Syncom Formulation (India) (NSE:SYNCOMF) Change In Receivables : ₹0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Syncom Formulation (India) Change In Receivables?

Syncom Formulation (India)'s change in receivables for the quarter that ended in Mar. 2024 was ₹0 Mil. It means Syncom Formulation (India)'s Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Syncom Formulation (India)'s change in receivables for the fiscal year that ended in Mar. 2024 was ₹-293 Mil. It means Syncom Formulation (India)'s Accounts Receivable increased by ₹293 Mil from Mar. 2023 to Mar. 2024 .

Syncom Formulation (India)'s Accounts Receivable for the quarter that ended in Mar. 2024 was ₹1,033 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Syncom Formulation (India)'s Days Sales Outstanding for the three months ended in Mar. 2024 was 126.40.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Syncom Formulation (India)'s liquidation value for the three months ended in Mar. 2024 was ₹1,031 Mil.

Syncom Formulation (India) Change In Receivables Historical Data

The historical data trend for Syncom Formulation (India)'s Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syncom Formulation (India) Change In Receivables Chart

Syncom Formulation (India) Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Change In Receivables

Get a 7-Day Free Trial

-6.80

-315.21

50.46

-74.11

-293.03

Syncom Formulation (India) Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Syncom Formulation (India) Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

Syncom Formulation (India) (NSE:SYNCOMF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Syncom Formulation (India)'s Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	1032.984	/	745.729	*	91
=	126.40

2. In Ben Graham's calculation of liquidation value, Syncom Formulation (India)'s accounts receivable are only considered to be worth 75% of book value:

Syncom Formulation (India)'s liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1315.649	-	1165.211	+	0.75 * 1032.984	+	0.5 * 210.815
=	1,031

Syncom Formulation (India) Change In Receivables Related Terms

Thank you for viewing the detailed overview of Syncom Formulation (India)'s Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Syncom Formulation (India) (NSE:SYNCOMF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syncom Formulation (India) Ltd (NSE:SYNCOMF) » Definitions » Change In Receivables

Traded in Other Exchanges

524470:India

Address

207, Saket Nagar, Near Saket Club, Indore, MP, IND, 452018

Website

https://www.sfil.in

Syncom Formulation (India) Ltd is in the business of pharmaceuticals. The company operates through three segments including manufacturing and dealings in Pharmaceutical drugs and formulations, Trading of commodities, and Renting of property. It manufactures and markets pharmaceutical formulation products in various dosage forms like tablets, capsules, liquids orals, liquids vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and Herbals. The company's product includes generic, antiviral, antidepressant, cough suppressant, electrolyte, histamine, estrogen, and much more. It generates maximum revenue through the Pharmaceutical drugs and formulations segment.

Syncom Formulation (India) (NSE:SYNCOMF) Headlines

No Headlines